Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Thyrocare Technologies announced the audio recording of its earnings conference call, held on May 12, 2026, for the quarter and financial year ended March 31, 2026, is now available on the company's website for investor access. The transcript will be shared shortly.
May 12 2026 14:05:00
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Thyrocare Technologies' Board approved altering its Memorandum of Association (MOA) to broaden the company's business scope within the healthcare and diagnostics ecosystem. This change, pending shareholder approval, enables the company to undertake a wider range of activities, including allied services and related products.
May 07 2026 19:05:00
Thyrocare Technologies Ltd - 539871 - Appointment Of Cost Auditors For The Financial Year 2026-27
Thyrocare's Board met on May 7, 2026, and recommended a final dividend of Rs. 7.00 per share for FY2025-26. The board also approved the appointment of new statutory and cost auditors, re-appointment of MD & CEO, and made changes to other directors.
May 07 2026 19:05:00
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Thyrocare Technologies' board approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term. This appointment is subject to shareholder approval at the upcoming AGM.
May 07 2026 19:05:00
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Change in Directorate
Thyrocare Technologies re-appointed Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for a five-year term, effective May 4, 2027, subject to shareholder approval. This ensures continued leadership for strategic initiatives.
May 07 2026 19:05:00
Thyrocare Technologies Ltd - 539871 - Corporate Action-Board approves Dividend
Thyrocare board recommended a final dividend of ₹7.00 per equity share for FY26. Including the interim dividend, the total payout for the fiscal year amounts to ₹9.33 per share (post bonus adjustment).
May 07 2026 19:05:00
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Thyrocare Technologies announced robust Q4 FY26 consolidated results, with revenue growing 20% YoY to Rs.223.95 cr and net profit soaring 128% YoY to Rs.48.70 cr. The company also reported strong annual growth for FY26.
May 07 2026 18:05:00
Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 07, 2026
Thyrocare Technologies board approved its FY26 audited financial results and recommended a final dividend of ₹7.00 per equity share. The board also re-appointed Rahul Guha as CMD for five years and approved a ₹5.50 crore investment in its wholly-owned subsidiary, Think Health Diagnostics Private Limited.
May 07 2026 17:05:00
Thyrocare Technologies Ltd - 539871 - Cancellation Of Earning Conference Call
Thyrocare Technologies announced the cancellation of its earnings conference call for analysts/investors, which was scheduled for May 07, 2026. The call was intended to discuss the company's Audited Financial Results for Q4 and FY26. A revised schedule will be provided later.
May 07 2026 17:05:00
Thyrocare Technologies Ltd - 539871 - Corporate Action-Board to consider Dividend
Thyrocare Technologies board to meet on May 07, 2026, to consider a final dividend for FY 2025-26. This decision is crucial for shareholder returns.
Apr 29 2026 13:04:00
Read More